NCT03916757 (GBM) is a Phase 2 clinical trial of V-Boost in Glioblastoma Multiforme, sponsored by Immunitor LLC.

Who is sponsoring NCT03916757?

NCT03916757 is sponsored by Immunitor LLC.

What drugs are being tested in NCT03916757?

Interventions in NCT03916757: V-Boost.

What condition does NCT03916757 study?

NCT03916757 studies Glioblastoma Multiforme, Glioma of Brain.

Is NCT03916757 still recruiting?

NCT03916757 is currently status unknown. Last updated 17 April 2019.

Last reviewed 2019-04-17 · How we verify

NCT03916757: GBM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer

Status unknown Phase 2 Last updated 17 April 2019

What this trial tests

Phase 2 trial testing V-Boost in Glioblastoma Multiforme in 20 participants. Status unknown.

Timeline

16 April 2019

Primary endpoint
15 April 2020

15 June 2020

Quick facts

Lead sponsor	Immunitor LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	16 April 2019
Primary completion	15 April 2020
Estimated completion	15 June 2020
Sites	1 location across Mongolia

Drugs / interventions tested

V-Boost — full drug profile →

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Glioma of Brain — all drugs for Glioma of Brain →

Sponsor

Immunitor LLC — full company profile →

Who can join

Adults 5 to 99, any sex, with Glioblastoma Multiforme or Glioma of Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM). V-Boost is an immunotherapy in which the patient's immune system will be modulated to eliminate tumor cells. V-Boost is made as an oral tablet which contains specially formulated hydrolyzed GBM antigens along with alloantigens. Patients are either newly diagnosed or with recurrent form of GBM who may have been subjected to surgery and/or chemo- or radiation therapy that ended up unsuccessful. The goal is to eradicate GBM tumor cells through daily oral administration of one pill of V-Boost immunotherapeutic vaccine, which so far has not shown any adverse reaction.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T, Hemadou A, Romero Garmendia I, Saleh M. · · 2020 · cited 89× · PMID 33154756 · DOI 10.3389/fimmu.2020.585616
Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
Miyazaki T, Ishikawa E, Sugii N, Matsuda M. · · 2020 · cited 30× · PMID 32707672 · DOI 10.3390/cancers12071960
Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities.
Njonkou R, Jackson CM, Woodworth GF, Hersh DS. · · 2022 · cited 14× · PMID 35020009 · DOI 10.1007/s00262-021-03131-y
A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.
Puig-Saenz C, Pearson JRD, Thomas JE, McArdle SEB. · · 2023 · cited 4× · PMID 37626597 · DOI 10.3390/biomedicines11082100

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting

Other Immunitor LLC trials

Trials by the same sponsor.

NCT04377243 — Immunotherapy of Chronic Kidney Failure · Phase 2 · unknown
NCT04380532 — Tableted COVID-19 Therapeutic Vaccine · Phase 1, PHASE2 · unknown
NCT03556566 — Open Label Immunotherapy Trial for Ovarian Cancer · Phase 2 · unknown
NCT03550755 — Immunotherapy of Cervical Cancer With V3-Cervix · Phase 2 · unknown
NCT03572361 — Open Label Immunotherapy Trial for Breast Cancer · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03916757 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunitor LLC
Last refreshed: 17 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03916757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing